L
Locus Biosciences
Biotech & Life Sciences · Morrisville, United States · Founded 2015
A biotechnology company that develops CRISPR-engineered precision antibacterial products MoreLess
Locus Biosciences operates in the biotechnology sector, focusing on the development of precision antibacterial products to treat infectious diseases and microbiome-related conditions. The company leverages CRISPR-Cas3 engineered bacteriophages, branded as crPhage™, to specifically target and eradicate harmful bacterial pathogens. Locus Biosciences serves clients in the healthcare and pharmaceutical industries, including partnerships with major pharmaceutical companies like Janssen Pharmaceuticals. The company operates in the global market, with a business model centered around the development, licensing, and commercialization of its proprietary technologies. Revenue is generated through licensing agreements, research collaborations, and potential future sales of approved therapeutic products.
Keywords: CRISPR, bacteriophage, infectious diseases, microbiome, biotechnology, precision medicine, healthcare, pharmaceuticals, licensing, commercialization.
Company overview
Locus Biosciences company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2015
- Headquarters
- Morrisville, United States
- Employees
- 61
- Open positions
- None listed
- Dealroom signal
- 72.1
Valuation & funding
Locus Biosciences funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| GRANTOther financing | Jan 2026 | $3.3M | — | US National Institute of Allergy and Infectious Diseases | ↗ |
| GRANTOther financing | Jan 2024 | $24M | — | US Biomedical Advanced Research and Development Authority | ↗ |
| SERIES BOther financing | May 2022 | $35M | $140M | Viking Global Investors · Tencent · Artis Ventures · Johnson & Johnson Innovation | ↗ |
| EARLY VCOther financing | Feb 2022 | $11M | $42M | Undisclosed | — |
| DEBTDebt | Oct 2021 | $25M | — | Hercules Capital | — |
| GRANTOther financing | Nov 2020 | CARB-X | — | ||
| DEBTDebt | Jul 2020 | Undisclosed | — | ||
| SERIES AOther financing | Jul 2018 | Undisclosed | — | ||
| SERIES AOther financing | Nov 2017 | Undisclosed | — | ||
| CONVERTIBLEOther financing | Jul 2017 | Tencent · North Carolina Biotechnology Center | — |
Growth signals
Locus Biosciences website traffic
Latest recorded traffic for Locus Biosciences is 4.5K monthly website visits, down 8.2% over the last three months. Locus Biosciences's team grew 0% over the past year.
Comparisons
Locus Biosciences compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Locus Biosciences's talent
Source: Dealroom Talent Intelligence.
Investors
10 investors on Locus Biosciences's cap table
Sourced from Dealroom's funding and investor records. Investor profile links are shown where available.
Global footprint
Where Locus Biosciences has talent and traffic
team presence
In the news
Latest news about Locus Biosciences
Recent press, funding announcements, and product moves mentioning Locus Biosciences — open to read from the original sources.
Market sentiment
What the market is saying about Locus Biosciences
An AI-synthesized read of the highest-engagement posts about Locus Biosciences on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Locus Biosciences’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.